Toronto, Ontario--(Newsfile Corp. - February 19, 2025) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), provides an update on various matters: Status of Failure to File Cease Trade Order/CSE Listing On August 6, 2024, the Company announced that the Ontario Securities Commission (the "OSC") issued a failure-to-file cease trade order (the "FFCTO") to the Corporation... Read More

Toronto, Ontario--(Newsfile Corp. - November 18, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia", or the "Company") announced that Jerry Habuda has resigned as a director effective November 12, 2024. Peter Rizakos was appointed on the same date by the remaining directors. Roger McIntyre resigned as a director and CEO effective November 13, 2024. The current directors of the Company are... Read More

Sale of Company's Assets Approved Toronto, Ontario--(Newsfile Corp. - October 10, 2024) - Braxia Scientific Corp . (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia", or the "Company"), is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders held on Wednesday, October 9, 2024. A total of 9.9% of the issued and outstanding common shares of the Company were represented either in... Read More

Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company") announced today that an annual general and special meeting (the "Meeting") of the common shareholders will be held in person at 10:00 a.m. (Toronto time) on Wednesday October 9, 2024, at 1430 Hurontario Street, Mississauga, Ontario, L5G 3H4. Please note that... Read More

Toronto, Ontario--(Newsfile Corp. - August 5, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FWB: 4960), ("Braxia Scientific", or the "Company"), today announced that the Ontario Securities Commission (the "OSC") issued a failure-to-file cease trade order (the "FFCTO") to the Company on August 2, 2024. The FFCTO is a result of the Company's failure to file its audited annual financial statements (the "Annual... Read More

Toronto, Ontario--(Newsfile Corp. - July 25, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), today announced further to its press release of July 15, 2024, that the Ontario Securities Commission (the "OSC") has denied the Company's application for a voluntary management cease trade order (the "MCTO") under National Policy 12-203 Management Cease Trade Orders... Read More

Toronto, Ontario--(Newsfile Corp. - July 15, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), today announced that it has made an application to the Ontario Securities Commission to approve a management cease trade order ("MCTO") under National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203"), which, if granted, will... Read More

Toronto, Ontario--(Newsfile Corp. - February 29, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and nine... Read More

Toronto, Ontario--(Newsfile Corp. - January 15, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the mandatory conversion of $2,935,714 in convertible debentures, which matured on December 31, 2023, into... Read More

Toronto, Ontario--(Newsfile Corp. - November 30, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and six months... Read More

Toronto, Ontario--(Newsfile Corp. - August 30, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months... Read More

Braxia Health ketamine treatments up 26% YoY in 2023 and revenue up 27% YoY Company completes dosing of final participant in Phase 2, multi-dose Psilocybin trial, results expected to be published prior to end of 2023 Company reviewing financing options, strategic partnerships and further cost reductions and organizational changes as required Toronto, Ontario--(Newsfile Corp. - July 31, 2023) - Braxia Scientific Corp. (CSE:... Read More

Company Taking Strategic Actions to Prioritize Clinic Expansion, Enhance Operational Effectiveness and Right Size Cost Structure This release adds information to the press release disseminated on June 9, 2023 Toronto, Ontario--(Newsfile Corp. - June 12, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia", or the "Company"), a medical research company with mental health clinics providing... Read More

Company Taking Strategic Actions to Prioritize Clinic Expansion, Enhance Operational Effectiveness and Right Size Cost Structure Toronto, Ontario--(Newsfile Corp. - June 9, 2023) - Braxia Scientific Corp. ( CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia", or the "Company"), a medical research company with mental health clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is... Read More

Toronto, Ontario--(Newsfile Corp. - March 16, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC PINK: BRAXF) (FWB: 4960) ("Braxia", or the "Company"), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, announces that Irwin Naturals Inc. ("Irwin") has terminated the non-binding amended and restated letter of intent ("LOI") for a... Read More

Braxia Health ketamine treatments up 29% YoY in Q3 2023 and revenue up 50.5% YoY Toronto, Ontario--(Newsfile Corp. - March 1, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its... Read More

Toronto, Ontario--(Newsfile Corp. - February 27, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia", or the "Company"), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is pleased to announce that it has closed the first tranche of its non-brokered offering, as described in its press release of February 7, 2023 (the... Read More

Braxia Scientific CEO Dr Roger McIntyre joined Steve Darling from Proactive to share news the company has agreed to a non-binding amended and restated letter of intent for a business combination with Irwin Naturals Inc. McIntyre told Proactive the transaction assembles an experienced management and scientific team in mental health treatment, research and development. The combined company will have 17 specialized mental... Read More

Toronto, Ontario--(Newsfile Corp. - February 7, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF) (FSE: 4960) ("Braxia", or the "Company"), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is pleased to announce an offering of up to 27,272,727 units of the Company (the " Units ") at a price of $0.055 per Unit for aggregate gross proceeds of up... Read More

Strategic transaction assembles an experienced management and scientific team world-renowned in the mental health treatment, research and development. Establishes large footprint of 17 specialized mental health clinics across North America, and 5 more under definitive agreement with Irwin Naturals, enhanced by a telehealth platform expected to extend access to critical treatments for millions of people across multiple states... Read More